CAR T-cell therapy in SLE: A systematic review
- PMID: 40749440
- DOI: 10.1016/j.semarthrit.2025.152786
CAR T-cell therapy in SLE: A systematic review
Abstract
Introduction: CAR T-cell therapy is poised to revolutionize the treatment of SLE. Several publications reported on small numbers of SLE patients treated with CAR-T.
Objective: To review and summarize the available clinical evidence published or presented to date on the use of CAR therapy in SLE.
Methods: We conducted a systematic review to evaluate all clinical studies assessing safety and efficacy outcomes of CAR therapy in SLE. For this review, we followed PRISMA recommendations. MEDLINE (PubMed), Embase, Scopus, and CENTRAL were consulted.
Results: The search strategy yielded 5905 results, of which 16 studies were included, encompassing 145 participants. Pooled analysis of the 102 individual SLEDAI scores available showed the mean baseline SLEDAI of 13.1 (95% CI 12.3-13.9) decreased to 2.3 (95% CI 1.5-3.1) after 6 months, and 1.4 (95% CI 0.3-2.4) after 12 months. DORIS remission was achieved in 45/64 patients (70%) and LLDAS in 50/56 (89%). CRS occurred in 81 (56%) participants, of which 80 (98%) were grade 1 or 2, and 1 (2%) grade 3. ICANS was reported in four patients, 1 grade 1, 1 grade 2, 1 grade 3, and 1 grade 4. Eleven patients (7.6%) developed serious infections, including one case of fatal pneumococcal meningitis.
Conclusion: This systematic review evaluated all the available clinical evidence on the use of CAR T-cell therapy in patients with SLE. The findings reinforce the efficacy of this treatment modality and underscore the need for further research to better define its role in SLE management.
Keywords: CAR T-cell therapy; Cell therapy; Systematic Review; Systemic lupus erythematosus.
Copyright © 2025. Published by Elsevier Inc.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Anca Askanase reports a relationship with AstraZeneca that includes: consulting or advisory and funding grants. Anca Askanase reports a relationship with Bristol Myers Squibb Co that includes: consulting or advisory and funding grants. Anca Askanase reports a relationship with Cabaletta Bio Inc that includes: consulting or advisory and funding grants. Anca Askanase reports a relationship with Idorsia Pharmaceuticals Ltd that includes: consulting or advisory and funding grants. Anca Askanase reports a relationship with Genentech Inc that includes: consulting or advisory and funding grants. Anca Askanase reports a relationship with Nkarta Inc that includes: consulting or advisory and funding grants. Anca Askanase reports a relationship with Sana Biotechnology Inc that includes: consulting or advisory and funding grants. Anca Askanase reports a relationship with Sanofi that includes: consulting or advisory and funding grants. Anca Askanase reports a relationship with UCB Inc that includes: consulting or advisory and funding grants. Anca Askanase reports a relationship with Abbvie that includes: consulting or advisory. Anca Askanase reports a relationship with Amgen Inc that includes: consulting or advisory. Anca Askanase reports a relationship with Aurinia that includes: consulting or advisory. Anca Askanase reports a relationship with Biogen that includes: consulting or advisory. Anca Askanase reports a relationship with Celgene that includes: consulting or advisory. Anca Askanase reports a relationship with Eli Lilly and Company that includes: consulting or advisory. Anca Askanase reports a relationship with Janssen that includes: consulting or advisory. Anca Askanase reports a relationship with GSK that includes: consulting or advisory. Anca Asknase reports a relationship with Mallinckrodt that includes: consulting or advisory. Anca Askanase reports a relationship with Pfizer that includes: consulting or advisory. Michel Sadelain reports a relationship with Fate Therapeutics Inc that includes: funding grants. Michel Sadelain reports a relationship with Alaya.bio that includes: funding grants. Michel Sadelain reports a relationship with Juno Therapeutics that includes: funding grants. Michel Sadelain reports a relationship with Celgene that includes: funding grants. Michel Sadelain reports a relationship with BMS that includes: funding grants. Michel Sadelain reports a relationship with Takeda that includes: funding grants. Michel Sadelain reports a relationship with Atara Biotherapeutics Inc that includes: funding grants. Michel Sadelain reports a relationship with Minerva Biotechnologies Corporation that includes: funding grants. Michel Sadelain reports a relationship with Senescea that includes: funding grants. Laura Geraldino-Pardilla reports a relationship with BMS that includes: funding grants. Laura Geraldino-Pardilla reports a relationship with AstraZeneca Pharmaceuticals LP that includes: funding grants. Laura Geraldino-Pardilla reports a relationship with Biogen Inc that includes: funding grants. Laura Geraldino-Pardilla reports a relationship with GSK that includes: funding grants. Laura Geraldino-Pardilla reports a relationship with Aurinia that includes: funding grants. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
